Psoralidin

Research use only, not for human use.

Psoralidin inhibits Akt phosphorylation and phosphatidylinositol 3-kinase activation and transcriptionally.

Psoralidin is a metabolic product from the seed of psoraleacorylifolia, possessing anti-inflammatory and immunomodulatory effects. Psoralidin inhibits lipopolysaccharide induced bone resorption by suppressing the inflammatory cytokines: TNF-α and IL-6 expression, as well as the ratio of RNAKL : OPG.

Cell Viability Assay Cell Line:ALDH- cells, ALDH+ cells, commercial breast cancer stem cells (BSCSs), and normal breast epithelial cells (MCF-12A) Concentration:10, 15, 50, and 25 μM Incubation Time:24?hours Result:IC50s of 18 to 21?μM for ALDH- cells, ALDH+ cells, commercial BCSCs. Apoptosis Analysis Cell Line:ALDH- cells, ALDH+ cells, and commercial BCSCs Concentration:20?and 30 μM Incubation Time:24?hours Result:No significant induction of apoptosis was observed for any of the three cell types following treatment at 20?μM. However, 53.60%, 44.1%, and 45.9% of cells were apoptotic at 30?μMin ALDH- cells, ALDH+ cells, and commercial BCSCs, respectively.

Animal Model:BALB/c mice Dosage:5 mg/kg Administration:Intraperitoneal application; 30 min before and 1 h after IR irradiation (20 Gy).Result:Anti-inflammatory effect in IR-irradiated mice.

Psoralidin

Others

Other Targets

Akt| Phosphatidylinositol 3-kinase

Others-Field

——

18642-23-4

336.34

C20H16O5

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (148.66 mM)

CC(=CCc1c(cc2c(c1)c1c(c3c(o1)cc(cc3)O)c(=O)o2)O)C

3,9-Dihydroxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one

(-20℃)

With Ice Pack

≥ 2 years